Literature DB >> 7841429

Maintenance of therapeutically active levels of isoniazid for prolonged periods in rabbits after a single implant of biodegradable polymer.

S Kailasam1, D Daneluzzi, P R Gangadharam.   

Abstract

SETTING: Poor patient compliance is the serious limiting factor in the chemotherapy of tuberculosis.
OBJECTIVE: To solve this problem we have been developing depot-drug delivery of antimycobacterial drugs. Earlier studies with mice using isoniazid in polylactic-co-glycolic acid (PLGA) co-polymer have shown that a single implant of the polymer could ensure sustained levels of free isoniazid for up to 8 weeks. Similar studies were not undertaken in rabbits.
DESIGN: The biodegradable PLGA polymer rods containing isoniazid were implanted on the back of the rabbits under anaesthesia in an isoniazid dose of 90 mg/kg. Concentrations of isoniazid and acetylisoniazid in serum and urine were determined by the high-performance liquid chromatography (HPLC) method at close intervals up to 96 h to study the burst-size, and later at weekly intervals up to 9 weeks to study the sustained levels. RESULTS AND
CONCLUSIONS: There was no abnormal release of isoniazid in the earlier periods. Concentrations of isoniazid > or = 0.2 microgram/ml were found both in serum and urine up to 63 days after implant. Urine specimen obtained at 6 weeks after giving the implant inhibited the growth of Mycobacterium tuberculosis in vitro as measured by the radiometric (Bactec) method. These findings in non-rodent animal species confirm the usefulness of the depot-drug delivery method of drug administration and warrant hopes for the successful treatment of tuberculosis avoiding the problem of non-compliance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7841429     DOI: 10.1016/0962-8479(94)90082-5

Source DB:  PubMed          Journal:  Tuber Lung Dis        ISSN: 0962-8479


  6 in total

1.  Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice.

Authors:  M Dutt; G K Khuller
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis.

Authors:  Qurrat Ul-Ain; Sadhna Sharma; G K Khuller
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

3.  In vitro and in vivo evaluations of biodegradable implants for hormone replacement therapy: effect of system design and PK-PD relationship.

Authors:  S Lin; P Y Chao; Y W Chien; S Sayani; S Kuma; M Mason; T Wes; A Yang; D Monkhouse
Journal:  AAPS PharmSciTech       Date:  2001-09-21       Impact factor: 3.246

4.  Novel drug delivery systems: desired feat for tuberculosis.

Authors:  Kirtipal Kaur; Anuj Gupta; R K Narang; R S R Murthy
Journal:  J Adv Pharm Technol Res       Date:  2010-04

Review 5.  Tuberculosis chemotherapy: current drug delivery approaches.

Authors:  Lisa Claire du Toit; Viness Pillay; Michael Paul Danckwerts
Journal:  Respir Res       Date:  2006-09-19

Review 6.  Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control.

Authors:  Afzal Hussain; Sima Singh; Sabya Sachi Das; Keshireddy Anjireddy; Subramanian Karpagam; Faiyaz Shakeel
Journal:  Curr Drug Deliv       Date:  2019       Impact factor: 2.565

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.